Comparative Study on the Duration and Efficacy of Various Botulinum Toxin Type A Injections for Reducing Masseteric Muscle Bite Force and Treating Facial Wrinkles.

OBJECTIVE: Botulinum toxin serotype A (BoNT/A) is widely used for minimal invasive aesthetic treatments. Different brands of BoNT/A exhibit structural variations. The aim of this study was to compare the duration and efficacy of various BoNT/A brands available in Thailand for reducing bite force and treating wrinkles. METHODS: Fifty participants were randomly assigned to one of five groups, with each group receiving a different BoNT/A brand, namely, incobotulinumtoxinA (IncoA), onabotulinumtoxinA (OnaA), abobotulinumtoxinA (AboA), letibotulinumtoxinA (LetiA), and prabotulinumtoxinA (PraboA). BoNT/A was administered to the masseter muscle and the upper face. Bite force was measured before injection and at 2, 4, 8, 12, 16, 20, and 24 weeks post-injection. Evaluation scores for wrinkle improvement were assessed after the treatment. RESULTS: The most significant reduction in bite force occurred between 2 and 4 weeks post-injection. PraboA demonstrated the most substantial reduction in bite force, while IncoA had the least effect. However, the percentage of bite force reduction did not exhibit statistical significance between BoNT/A types. Additionally, the reduction in bite force for all BoNT/A types was reversed at 4 months post-injection. More than half of the participants experienced improvement beyond 16 weeks. CONCLUSIONS: The structural differences among BoNT/A brands did not significantly affect the longevity and efficacy of bite force reduction and wrinkle treatment. TRIAL REGISTRATION: ClinicalTrials.gov identifier: TCTR20211205001 (registered 4 Dec 2021).

Shear bond strength of adhesive cement to zirconia: Effect of added proportion of yttria for stabilization.

STATEMENT OF PROBLEM: Zirconium dioxide (zirconia) cannot be etched in a clinical setting, but zirconia restorations with minimal to no micromechanical bonding are approved and widely used in contemporary dentistry. However, information on the shear bond strength of zirconia and adhesive cement, on the effect of an added proportion of yttria, and on the effect of aging is lacking. PURPOSE: The purpose of this in vitro study was to evaluate the shear bond strength of cement luted to zirconia and the effect of aging. MATERIAL AND METHODS: A total of 131 test specimens were made from 4 zirconia materials with different amounts of yttria added to formulate yttria-partially stabilized zirconia (Y-PSZ); 3Y-PSZ (n=32), 4Y-PSZ (n=34), and 2 5Y-PSZs (n=32 and n=33). A dual-polymerizing cement and 10-methacryloyloxydecyl dihydrogen phosphate-containing primer were used. All specimens were stored in water at 37 °C, half of them for 24 hours and the other half for 6 months. After aging, the specimens were subjected to a shear bond strength test with a notched crosshead according to the International Organization for Standardization (ISO) 29022:2013 standard. The data were analyzed using the independent 2-sample t test, ANOVA, and the Levene test (α=.05). RESULTS: The 3Y-PSZ material had higher mean ±standard deviation shear bond strength (31.83 ±12.80 MPa) compared with 4Y-PSZ (23.34 ±7.66 MPa) after 24 hours of aging in water and higher (28.98 ±14.03 MPa) than 4Y-PSZ (14.35 ±9.62 MPa) and one of the 5Y-PSZ (16.05 ±11.34 MPa) after 6 months. Debonding before loading occurred in all groups except for one of the 5Y-PSZ groups. CONCLUSIONS: Zirconia without macromechanical retention, regardless of an added proportion of yttria, showed high shear bond strength, but the tested materials also had a high coefficient of variance, which, in practice, leads to the risk of the occasional debonding of zirconia restorations.

Duration of bite force reduction following a single injection of botulinum toxin in the masseter muscle bilaterally: A one-year non-randomized trial.

BACKGROUND: Previous studies concerning the effect of botulinum toxin in masseter muscle have mainly reported effects observed through inspection of facial features or differences in pain levels. One systematic review of studies utilizing objective measurements reported that long-term muscular effect of botulinum neurotoxin injections into masseter muscle was inconclusive. OBJECTIVE: To evaluate the duration of reduced maximal voluntary bite force (MVBF) after botulinum toxin intervention. METHODS: The intervention group was comprised of individuals seeking aesthetic treatment for masseter reduction (n = 20), the reference group (n = 12) comprised of individuals with no intervention. Intervention through 25 units of Xeomin® (Merz Pharma GmbH & Co KGaA, Frankfurt am Main, Germany) botulinum neurotoxin type A injected into the masseter muscles bilaterally (totalling 50 units). A reference group did not receive any intervention. MVBF was measured in Newtons using a strain gauge meter at the incisors and first molars. MVBF was measured at baseline, at 4 weeks, 3 months, 6 months, and after 1 year. RESULTS: Both groups were similar in terms of bite force, sex and age at baseline. MVBF remained similar compared to baseline in the reference group. At 3 months, a significant reduction at all measurement points was observed in the intervention group; at 6 months, this reduction was no longer significant. CONCLUSION: A single intervention of 50 units of botulinum neurotoxin results in a reversible MVBF reduction of at least 3 months, although a visually discernable reduction may be more long-lasting.

The effect of botulinum toxin injections on bruxism: A systematic review.

OBJECTIVE: To systematize evidence on the efficacy of botulinum toxin type A (BTA) in the treatment of bruxism measured through bite force or electromyography (EMG) at the masseter muscle. METHOD: Identification of relevant articles through databases PubMed, Web of Science, SCOPUS, Ovid and EBSCO and manual search were performed for sources from review articles. Studies scoring less than 3 on the Jadad Scale were excluded. RESULTS: Four articles were included after an exclusion of 333 articles. 3 articles measured EMG and 1 bite force. 1 article did not record a significant drop of activity, 1 article recorded reduction midway and at final endpoint. 2 articles recorded initial reduction, but a non significant difference at later follow up. CONCLUSION: The available research is inconclusive and does not show enough evidence that bruxism can be treated with BTA injections. However, promising results have been shown in individual studies and further research in this area is needed.

Bond strength of surface-treated novel high translucent zirconia to enamel.

Aim: The aim of the present study was to evaluate the shear bond strength of zirconia, stabilised with 5% yttria, luted to enamel and to evaluate the fracture pattern at loss of retention. Methods: A total of 53 test specimen were manufactured from two partially stabilised zirconia materials, Zirkonzahn Prettau Anterior (ZPA) (n = 16) and Whitepeaks CopraSmile Symphony 5 layer (WCS) (n = 18), and a lithium disilicate (Ivoclar e.Max Press) (n = 19) acting as control. All test specimens were cemented to human enamel with Variolink Esthetic DC and then subjected to a shear bond strength test. Fracture and surface analysis were performed using light and scanning electron microscope. Results: No significant differences in shear bond strength were detected when analysing the three groups. Dividing them according to the fracture pattern significant difference in shear bond strength between the two zirconia groups could be seen analysing test bodies with failure of adhesion to the test body, but not to enamel. The ZPA had higher shear bond strength (23.68 MPa) than WCS (13.00 MPa). No significant differences were seen compared to the control group (19.02 MPa). Conclusion: Partially stabilised zirconia shows potential as a material to be used where macro mechanical bonding is not possible, although this study does not reveal how or if the bonding deteriorates over time.